In addition, treatment of HER2+ human breast cancer xenografts with the Tat-BECN1 autophagy-inducing peptide induced autophagy in vivo within the tumor, compromised the HER2/BECN1 interaction, induced a unique transcriptional profile and, most importantly, greatly inhibited tumor growth (Vega-Rubin-de-Celis et al., 2018; Vega-Rubin-de-Celis et al., 2020). This evidence concerns the gene ERBB2 and breast carcinoma.